ArticleHormone research in paediatrics2026
Predictors of Response to Growth Hormone Treatment and Final Height in Medulloblastoma Survivors.
Article in Hormone research in paediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAbnormal growth patterns and impaired final height (FH) are well-recognized long-term complications of childhood medulloblastoma; however, data regarding response to growth hormone treatment (GHT) and determinants of FH are scarce. We aim to describe growth characteristics and response to GHT in survivors of childhood medulloblastoma, and to identify factors associated with FH outcome.
methodsA retrospective study comprising all pediatric patients treated for medulloblastoma in a tertiary care center between 1987 and 2023 and followed up for at least 1 year following diagnosis.
resultsA total of 65/67 patients included in the final analysis (97%) exhibited growth retardation, of whom 38 (58%) were diagnosed with GH deficiency, and 26 were treated with GH. Fifteen of the GH-treated patients achieved FH, with a mean FH-SDS of -1.42 ± 1.47. Only eight (53%) achieved FH within the normal range. FH-SDS of survivors not treated with GH (-1.72 ± 1.25) was lower than that of GH-treated survivors, but this difference did not reach statistical significance. The most important predictor of FH outcome in GH-treated patients was height-SDS at initiation of treatment.
conclusionGrowth retardation and GH deficiency are observed in the vast majority of medulloblastoma patients. Our results suggest that early identification and treatment of GH deficiency are crucial for optimization of FH outcome. Long-term safety of GHT is still a concern and should be discussed with the family prior to initiating treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.